Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Fludarabine, Cyclophosphamide, and Rituximab in CLL
NCT00003659Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 1998
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 1998; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00003659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003659.